May 7-10, 2018 TIDES: Oligonucleotide & Hynes Convention Center Therapeutics Boston, MA THE LARGEST MEETING TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE PRODUCTS FROM EARLY DISCOVERY TO LATE-STAGE DEVELOPMENT & COMMERCIALIZATION Featuring Industry Experts to Help You Fast-Track Product Development

ADVANCES IN DISCOVERY OF DRUG CARRIERS SEMAGLUTIDE

Robert S. Langer, Sc.D. Jesper Lau, Ph.D. Vice President Koch Institute Professor Protein & Peptide Chemistry MIT Novo Nordisk A/S, Denmark

mRNA RNAI THERAPEUTICS: THERAPEUTICS PATISIRAN

Stéphane Bancel John Maraganore, Ph.D. Chief Executive Officer Chief Executive Officer Therapeutics

Diamond Sponsor: Event Partner: www.TIDESevent.com TIDES: THE INDUSTRY’S FLAGSHIP MEETING FOR OLIGONUCLEOTIDE Oligonucleotide & Peptide Therapeutics AND PEPTIDE SCIENCE, TECHNOLOGY AND NETWORKING

SCIENCE “TIDES is the premier venue to actually network with the peptide Accelerate your pipeline of oligonucleotide and peptide community. It attracts the therapeutics to market by applying best practices and research community up lessons learned from 125+ case studies and new data to the clinical community presentations from global industry leaders working – it covers the entire across the entire spectrum of development and spectrum of peptide production. science.” - Dr. Alex Fässler, COO, Bachem AG

TECHNOLOGY

Bring your product to market by meeting 90+ leading “TIDES is a ‘must-go’ product and service providers showcasing live conference for scientists technology demonstrations in our exhibit hall. working in the peptide/ oligonucleotide area” – George Wang, Analytical Chemist, Bristol-Myers Squibb

NETWORKING ”Definitely the best

Connect with 1000+ scientists and executives from 30 meeting in the US for countries focused in oligonucleotide and peptide development companies developing and production during luncheons, cocktail receptions and peptide therapeutics“

networking breaks. Networking has never been easier with the – Rodney Lax, Ph.D., Senior Director, included TIDES app that allows you to view the attendee list PolyPeptide Group and schedule meetings before, during and after the event.

For up-to-date program information and new abstracts, visit: www.TIDESevent.com 2 AGENDA AT-A-GLANCE MONDAY, MAY 7, 2018 • Pre-Conference Workshops 8:00 am - Workshop #1: Mass Spectrometry for Workshop #2: An Introduction to messenger RNA Workshop #3: Risk-Based Approaches to CMC Workshop #4: Novel Technologies for 12:00 pm and Oligonucleotides (mRNA) Therapeutics Development of Therapeutic Oligonucleotides Manufacturing Peptides Workshop #8: The Path to a Successful 1:00 pm - Workshop #5: Peptide Aggregation Challenges from Workshop #6: An Introduction to CRISPR and Genome Workshop #7: Lessons from The Peptide Field that Can Oligonucleotide IND/IMPD Submission: Regulatory, 5:00 pm API to Drug Product Editing Applications Be Applied to Oligonucleotides Nonclinical and CMC Perspectives 5:30 pm- 8:30 pm TIDES Brewery Event Co-Sponsored by Thermo Fisher Scientific and KNect365 TUESDAY, MAY 8, 2018 • Main Conference Exhibit Hall & Poster Viewing Hours: 2:45 pm-7:00 pm

8:00 am - KEYNOTE SESSION: Dr. Robert Langer, Massachusetts Institute of Technology John Maraganore, Ph.D., Alnylam Pharmaceuticals 11:45 am  Jesper Lau, Ph.D., Novo Nordisk A/S, Denmark Stéphane Bancel, Moderna Therapeutics 11:45 pm - 12:55 pm Spotlight Luncheon Presentations Sponsored by GAP Peptides, Nagase, TriLink 12:55 pm -2:45 pm Plenary Session 2:45 pm - 3:25 pm Grand Opening of Poster and Exhibit Hall and Networking Refreshment Break 3:25 pm - 5:30 pm PLENARY SESSION 5:30 pm - 7:00 pm Networking Reception in Poster and Exhibit Hall Sponsored by Ajinomoto and Ribobio WEDNESDAY, MAY 9, 2018 • Main Conference Exhibit Hall & Poster Viewing Hours: 10:00 am – 6:45 pm 7:45 am - 8:15 am Breakfast Spotlight Presentation Sponsored by ST Pharm Oligonucleotide Discovery, Preclinical Oligonucleotide Chemistry, Peptide Discovery, Peptide Chemistry and Clinical Manufacturing and Controls Preclinical and Clinical Manufacturing and Controls 8:25 am - 12:20 pm RNA Therapeutics: from Bench-to-Bedside Oligonucleotide Manufacturing Technologies for Peptide Lead Discovery CMC, Quality and Regulatory Aspects of Peptide API’s 12:20 pm - 12:50 pm Spotlight Presentations Sponsored by BioSpring GmbH, Ajinomoto Co. Inc., Polymun Scientific GmbH, USP 12:50 pm - 1:55 pm Networking Luncheon in Poster and Exhibit Hall Oligonucleotide Discovery, Oligonucleotide Chemistry, Peptide Discovery, Peptide Chemistry Delivery of Macromolecular mRNA, CRISPR and Hot Preclinical and Clinical Manufacturing and Controls Preclinical and Clinical Manufacturing and Controls Therapeutics Topics in Oligonucleotides Delivery: Cross-Fertilizing Ideas 1:55 pm - mRNA Discovery and Development 5:45 pm Nonclinical Development of Oligonucleotides Peptide Preclinical and Clinical from Oligonucleotides, Peptides, mRNA and CRISPR mRNA CMC and Manufacturing 5:45 pm - 6:45 pm Networking Reception in Poster and Exhibit Hall Sponsored by Bachem THURSDAY, MAY 10, 2018 • Main Conference Exhibit Hall & Poster Viewing Hours: 10:00 am-2:00 pm Oligonucleotide Discovery, Oligonucleotide Chemistry, Peptide Discovery, Peptide Chemistry mRNA, CRISPR and Hot Topics in Preclinical and Clinical Manufacturing and Controls Preclinical and Clinical Manufacturing and Controls Oligonucleotides Starting Materials Improving Peptide Synthesis and Peptide Properties CRISPR Therapeutics 8:25 am - Oligonucleotide Preclinical and 12:15 pm Clinical Development Analytics for Oligonucleotides New Generic Peptide Regulatory Challenges Hot Topics in Oligonucleotides

12:20 pm - 12:50 pm Spotlight Presentations Sponsored by CordenPharma, Intertek, Sumitomo Chemical 12:50 pm - 1:55 pm Networking Luncheon in Poster and Exhibit Hall Oligonucleotide Discovery, Oligonucleotide Chemistry, Peptide Chemistry Peptide Discovery, mRNA, CRISPR and Hot Topics in Preclinical and Clinical Manufacturing and Controls Manufacturing and Controls Preclinical and Clinical Oligonucleotides 1:55 pm - Oligonucleotide Preclinical and Oligonucleotide and Peptide Drug Product Strategies Peptide Delivery mRNA Delivery 3:30 pm Clinical Development

Register Early for Best Savings • www.TIDESevent.com • 888-670-8200 3 MONDAY, MAY 7, 2018 • PRE-CONFERENCE WORKSHOPS • CHOOSE TWO HALF-DAY WORKSHOPS 7:15 Workshop Registration Workshop #1: Workshop #2: MASS SPECTROMETRY FOR PEPTIDES AND OLIGONUCLEOTIDES AN INTRODUCTION TO messenger RNA (mRNA) THERAPEUTICS Morning Half-Day Workshop • 8:00am-12:00pm Morning Half-Day Workshop • 8:00am-12:00pm

8:00 Workshop Leader’s Welcome and Opening Remarks 8:00 Workshop Leader’s Welcome and Opening Remarks Fanyu Meng, Ph.D., Principal Scientist, Analytical Research and Development, Merck Research Labs, Merck & Co., Inc. Jim Thompson, Ph.D., Head CMC Project Management, Moderna Therapeutics 8:15 Contribution of High Resolution Mass Spectrometry in Synthetic Peptides: Importance of 8:15 Introduction to mRNA Therapeutics Detailed Impurity Characterization for Better Manufacturing Jim Thompson, Ph.D., Head CMC Project Management, Moderna Therapeutics David Cosquer, Mass Spectrometry Specialist, Analytical Development, Polypeptide, Belgium 9:00 Design and Manufacturing of Chemically Modified Messenger RNA Therapeutics 8:45 LC/MS Oligonucleotide Mass Fingerprinting Enables Rapid Characterization of Critical Quality Anton McCaffrey, Ph.D., Senior Director of Research and Development, Biology, TriLink , Inc. Attributes in Therapeutic mRNA Serenus Hua, Ph.D., Senior Scientist, Moderna Therapeutics 10:00 Networking Refreshment Break 9:15  Assessment of Peptide Metabolism at the Subcutaneous Injection Site by Liquid 10:30 Delivery Strategies for mRNAs -high Resolution Mass Spectrometry Luis Brito, Ph.D., Director, Formulation Design, Moderna Therapeutics Simone Esposito, Ph.D., DMPK Research Scientist, Chemistry - Preclinical Research Unit, IRBM Science Park, Italy 11:00 Applications of mRNA Therapeutics 9:45 Networking Refreshment Break Patrick Baumhof, Ph.D., Vice President, Formulation and Delivery, Curevac, Germany 10:15 Oligonucleotide Characterization: Applications and Uses of Mass Spectrometry 11:30 Panel Discussion and Q&A Gangani Silva, Ph.D., Senior Scientist, Analytical Development, Nitto Avecia 12:00 Close of Workshop 10:45 LC Peak Purity Assessment Using a Novel LC-MS Data Processing Approach Patrik Plattner, Ph.D., Group Leader Mass Spectrometry Service, Bachem AG, Switzerland 11:15 Mass Spectrometry Methodologies for Analytical Control of Synthetic Oligonucleotides Fanyu Meng, Ph.D., Principal Scientist, Analytical Research and Development, Merck Research Labs, Merck & Co., Inc. 11:45 Concluding Remarks and Discussion 12:00 Close of Workshop

Workshop #3: Workshop #4: RISK-BASED APPROACHES TO CMC DEVELOPMENT OF NOVEL TECHNOLOGIES FOR MANUFACTURING PEPTIDES THERAPEUTIC OLIGONUCLEOTIDES Morning Half-Day Workshop • 8:00am-12:00pm Morning Half-Day Workshop • 8:00am-12:00pm There is a growing trend in the towards accelerated development of therapeutics to address unmet 8:00 Workshop Leader’s Welcome and Opening Remarks medical needs. The shorter timelines coupled with increasing complexity of the development candidates and/or delivery Trishul Shah, Director, Business Development, North America, PolyPeptide systems presents extraordinary challenges for managing the chemistry, manufacturing and controls activities. Key to regulatory 8:15 and operational success is a risk based approach to management of manufacturing, product quality and supply chain. This Chemo-enzymatic Synthesis (CEPS) of Exenatide: Laboratory Scale Development Timo Nuijens, Ph.D., Lead Scientist, EnzyPep BV, The Netherlands workshop will address important concepts for balancing and mitigating a variety of risks (safety, economic or regulatory, etc.) towards successful clinical development, regulatory approval and commercialization of therapeutic oligonucleotides. 8:45 Cost Efficient Peptide Purification via ZEOsphere DRP Mixed-Mode Chromatography 8:00 Workshop Co-Leaders’ Welcome and Opening Remarks Jürgen Machielse, Business Development Director Spherical Gels, Zeochem, Switzerland G. Susan Srivatsa, Ph.D., President, ElixinPharma 9:00 Towards Commercial Manufacturing of Therapeutic Peptides Using Chemo-enzymatic Peptide Fran Wincott, Ph.D., Wincott & Associates, LLC Synthesis (CEPS) 8:20 Selection and Justification of Regulatory Starting Materials Jan Pawlas, Ph.D., Scientist, PolyPeptide Group, Sweden Paul McCormac, Ph.D., Executive Director, Bio-therapeutic Pharmaceutical Sciences 9:30 Bringing Continuous Manufacturing into Peptide Manufacturing 9:00 Impurities in Oligonucleotide Drug Substances and Drug Products: Safety Considerations Andreas Segerros, CEO, Swedish Biomimetics 3000® Ltd. Tom Zanardi, Ph.D., Director, Toxicology, 10:00 Networking Refreshment Break 9:40 Networking Refreshment Break 10:30 Group-Assisted Purification (GAP) Technology and Its Future Potential for Peptide Synthesis 10:10 Planning for Oligonucleotide Supply: Personalized Medicine to Large Scale Markets Cole Seifert, Ph.D., Chief Scientific Officer, GAP Peptides, LLC Hans Kistemaker, Ph.D., Senior Scientist, Chemistry & Manufacturing, ProQR Therapeutics, The Netherlands 11:00 Unlocking the Potential for the Future of SPPS 10:50 Case Study: Evolution of the Rent, Buy or DIY Strategy Jon Holbech Rasmussen, Ph.D., Director, Global Development, PolyPeptide Group, Sweden Lubomir Nechev, Ph.D., Vice President, Process Sciences, Alnylam Pharmaceuticals 11:30 Panel Discussion 11:30 Panel Discussion 12:00 Close of Workshop and Lunch 12:00 Close of Workshop and Lunch For up-to-date program information and new abstracts, visit: www.TIDESevent.com 4 MONDAY, MAY 7, 2018 • PRE-CONFERENCE WORKSHOPS • CHOOSE TWO HALF-DAY WORKSHOPS Workshop #5: Workshop #6: PEPTIDE AGGREGATION CHALLENGES FROM API TO DRUG PRODUCT AN INTRODUCTION TO CRISPR AND GENOME EDITING APPLICATIONS Afternoon Half-Day Workshop • 1:00pm-5:00pm Afternoon Half-Day Workshop • 1:00pm-5:00pm

1:00 Workshop Leader’s Welcome and Opening Remarks 1:00 Workshop Leader’s Welcome and Opening Remarks Trishul Shah, Director, Business Development, North America, PolyPeptide Cecilia Fernández, Ph.D., Senior Director, Platform Strategy and Operations, Editas Medicine 1:15 Peptide Aggregation 1:15 CRISPR’s Road to the Clinic Juerg Tschopp, Ph.D., Chief Executive Officer & President, Stratum Medical Corporation TJ Cradick, Ph.D., Head of Genome Editing, CRISPR Therapeutics 1:45 Development of High Quality CRISPR/CAS9 Agents 2:00 Assessment of Deamidation and Aggregation of Peptide Variants Terence Ta, Ph.D., Scientist II, Editas Medicine Mohammad Al-Sayah, Ph.D., Senior Scientist, , Inc. 2:15 Genome instability and Cas9 specificity 2:45 Networking Refreshment Break Tom Barnes, Ph.D., Senior Vice President, Innovative Sciences, Intellia Therapeutics 3:15 The Effect of Peptide Aggregation on Downstream Purification: A DISASTER 2:45 Networking Refreshment Break Imre Sallay, Ph.D., Manager, Technical Sales, DAISOGEL Group, Osaka Soda, Co., Ltd., Japan 3:15 Peptide Technology to Deliver CRISPR Ribonucleoprotein in Cells 4:00 Solid-State NMR Investigation of Insoluble Aggregation of Peptide Drugs David Guay, Ph.D., Research Director, Feldan Therapeutics, Canada Yongchao Su, Ph.D., Associate Principal Scientist, Merck & Co. 3:45 Delivery of CRISPR/Cas RNP Using Polymer Nanoparticle System Kunwoo Lee, Ph.D., Chief Executive Officer, GenEdit 4:30 Panel Discussion 4:15 Panel Discussion 5:00 Close of Workshop 5:00 Close of Workshop Workshop #7: Workshop #8: LESSONS FROM THE PEPTIDE FIELD THAT CAN BE APPLIED TO THE PATH TO A SUCCESSFUL OLIGONUCLEOTIDE IND/IMPD SUBMISSION: OLIGONUCLEOTIDES REGULATORY, NONCLINICAL AND CMC PERSPECTIVES Afternoon Half-Day Workshop • 1:00pm-5:00pm Afternoon Half-Day Workshop • 1:00pm-5:00pm

1:00 Workshop Leader’s Welcome and Opening Remarks 1:00 Workshop Leader’s Welcome and Opening Remarks Gary Musso, Ph.D., President, Musso and Associates LLC Jennifer Lockridge, Ph.D., SVP, Program Development, Dicerna Pharmaceuticals, Inc. 1:10 Introductory Presentation on Peptide Chemistry Michael Verlander, President, Proactive Quality Compliance, Inc. 1:15 Regulatory Perspectives and Points to Consider in Making Successful Oligonucleotide IND/CTA Submissions 1:35 Synergy between Synthesis of Oligonucleotide and Peptide: From Concepts to Practical Applications Yogesh S. Sanghvi, Ph.D., President, Rasayan, Inc. Paul Manley, President and Principal Consultant, Orvieto Consulting 2:00 A Triple Contemplation - Regulatory Considerations on Recombinant Proteins, Synthetic 2:00 CMC Perspectives on Oligonucleotides Peptides and Oligonucleotides Vidhya Gopalakrishnan, Ph.D., Senior Vice President, Pharmaceutical Development, , Inc. René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical , BfArM Federal Institute for Drugs and 2:45 Networking Refreshment Break Medical Devices, Germany 2:45 Networking Refreshment Break 3:15 Considerations for the Early Preclinical Development of Oligonucleotide-based Therapeutics 3:15 An Engineer’s Perspective on Oligonucleotide Manufacturing and Applications from the Peptide Field Sarah Voytek, Ph.D., Associate Director, Preclinical Development, Bluebird Bio Christina Nacos, Associate Director, Oligonucleotides, Corden Pharma Colorado 4:00 Case Study: Lessons Learned from IND/IMPD Submissions for DCR-PH1, 3:40 Peptide and Oligonucleotide Therapeutics: Bioanalytical Challenges and Lessons Learned A Synthetic siRNA in a Lipid Nanoparticle Formulation Rafiq Islam, Senior Director Bioanalytical Services, Celerion Jennifer Lockridge, SVP, Program Development, Dicerna Pharmaceuticals, Inc. 4:05 Alternative Manufacturing Strategies and Concepts Used on Peptides; Considerations for Use in Oligonucleotides 4:30 Panel Discussion Gary Musso, Ph.D., President, Musso and Associates LLC 5:00 Close of Workshop 4:30 Panel Discussion 5:00 Close of Workshop See what’s brewing at Harpoon! Join us at this exclusive TIDES event at the Harpoon Brewery & Beer Hall, located in Boston’s Seaport District. Harpoon offers a full selection of Harpoon beers straight from the source along with TIDES BREWERY EVENT delicious pretzels to pair with your pint. Cap off your evening by taking a guided tour of the brewery or challenge a May 7 from 5:30pm-8:30pm coworker to a game of giant Jenga! This is the perfect place to enjoy beer with TIDES attendees and our sponsor Thermo Fisher Scientific. Co-Sponsored by and All registered TIDES attendees are welcome to RSVP, but space is limited! Registered attendees may RSVP here:https://www.surveymonkey.com/r/TIDES2018breweryRSVP Register Early for Best Savings • www.TIDESevent.com • 888-670-8200 5 TUESDAY, MAY 8, 2018 • KEYNOTE SESSION

7:00 Registration and Coffee 11:45-12:55 8:00 Chairperson’s Remarks SPOTLIGHT PRESENTATION Muthiah (Mano) Manoharan, Ph.D., Senior Vice President of , Alnylam Pharmaceuticals LUNCHEONS

8:10 Advances in Drug Carriers of Medicine Dr. Robert Langer 11:45 A New Method of Peptide Synthesis David H. Koch Institute Professor,  via Group-Assisted Purification Koch Institute of Integrative Cancer Research, (GAP) Technology Massachusetts Institute of Technology Cole Seifert, Ph.D., Chief Scientific Officer, GAP Peptides, LLC 8:55 Keynote Q&A

9:00 RNAi Therapeutics Delivered: Patisiran and Beyond 11:45 Solution-phase Synthesis of Oligonucleotides via Segmental John Maraganore, Ph.D. Approach Chief Executive Officer, Alnylam Pharmaceuticals Mamoru Hyodo, Ph.D., Chief Researcher, R&D Unit, Shikoku- Nucleic Acid Chemistry (S-NAC), Japan 9:40 Keynote Q&A

9:45 Networking Refreshment Break

10:15 The Discovery of Semaglutide – A Journey from 11:45 Advantages of in vivo DNA Ala Scan to Structural Design of GLP-1 Analogues Barcoding in Nanoparticle Selection Jesper Lau, Ph.D. and Therapeutic Gene Editing at the Target Site with CRISPR/CAS9 for Vice President, Protein & Peptide Chemistry, Novo Nordisk A/S, β-thalassemia Denmark James Dahlman, Ph.D., Assistant Professor, 10:55 Keynote Q&A Biomedical Engineering, Georgia Institute of Technology and Emory Medical School Mike Houston, Ph.D., Chief Scientific Officer, TriLink BioTechnologies 11:00 Thoughts on Building a Biotech Company Enabled TJ Cradick, Ph.D., Head of Genome Editing, by New Science CRISPR Therapeutics Stéphane Bancel Chief Executive Officer, Moderna Therapeutics

11:40 Keynote Q&A

For up-to-date program information and new abstracts, visit: www.TIDESevent.com 6 TUESDAY, MAY 8, 2018 • PLENARY SESSION

12:55 Chairperson’s Remarks 4:00 CMC Regulatory Perspectives and Strategies: Integrating Cecilia Fernández, Ph.D., Senior Director, Platform Strategy and Operations, Experiences from Different Product Modalities to Accelerate Editas Medicine Development of New Molecules Allison Wolf, Principal Research Scientist, Global Regulatory Affairs CMC, 1:00 Fireside Chat: The Emergence of CRISPR Therapeutics Eli Lilly Bill Lundberg, M.D., Chief Scientific Officer, CRISPR Therapeutics 4:30 SPINRAZA® () Approval: CMC Strategies and Vic Myer, Ph.D., Chief Technology Officer, Editas Medicine Lessons Learned Tom Barnes, Ph.D., Senior Vice President, Innovative Sciences, Firoz D. Antia, Ph.D., Director, Antisense Oligonucleotide Process Development Intellia Therapeutics and Manufacturing,

1:45 MC4R Pathway Defects: Treatment of Rare Monogenic Forms 5:00 CMC Regulatory Panel Discussion of Obesity Moderator: Lex Van der Ploeg, Ph.D., Chief Scientific Officer, Rhythm Pharmaceuticals G. Susan Srivatsa, Ph.D., President, ElixinPharma Panelists: 2:15 Launching Clinical Antisense Oligonucleotide Manufacturing René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, Capability in a Biologics Company BfArM Federal Institute for Drugs and Medical Devices, Germany Sheron Branham, Associate Director, ASO Process Engineering and Allison Wolf, Principal Research Scientist, Global Regulatory Affairs CMC, Manufacturing, Drug Product Facility, Biogen Eli Lilly 2:45  Grand Opening of Poster and Exhibit Hall Firoz D. Antia, Ph.D., Director, Antisense Oligonucleotide Process Development and Networking Refreshment Break and Manufacturing, Biogen

CMC for Oligonucleotides and Peptides: 5:30pm-7:00pm Current Regulatory Trends Networking Reception in Poster and Exhibit Hall Join fellow attendees and speakers for the 3:25 Chairperson’s Remarks TIDES opening night networking reception. G. Susan Srivatsa, Ph.D., President, ElixinPharma Enjoy drinks and appetizers with colleagues while viewing the exhibits and 3:30 CMC Regulatory Considerations for Oligonucleotides and scientific poster sessions. Peptides: What Are the Common Questions and Challenges Faced Sponsored by by Both Oligo and Peptide Developers René Thürmer, Ph.D., Deputy Head, Unit Pharmaceutical Biotechnology, BfArM Federal Institute for Drugs and Medical Devices, Germany and

Register Early for Best Savings • www.TIDESevent.com • 888-670-8200 7 WEDNESDAY, MAY 9, 2018 Oligonucleotide Discovery, Oligonucleotide Chemistry, Peptide Discovery, Peptide Chemistry Preclinical and Clinical Manufacturing and Controls Preclinical and Clinical Manufacturing and Controls 7:30 Registration and Coffee Breakfast Spotlight Presentation 7:45- Readiness to One-stop Manufacturing Service for Oligonucleotides GMP Liposome Production from Microfluidics to Large-scale 8:15 and Phosphoramidites for Commercial Scale Charalampos Koutsoulas, Ph.D., Head of Liposome R&D, Polymun Scientific GmbH, Austria Kyeong Eun Jung, Ph.D., Senior Vice President, Head of Oligo and R&D Division, ST Pharm, South Korea 8:25 (8:00) Chairperson’s Welcome and Opening Remarks Chairperson’s Remarks Chairperson’s Remarks Chairperson’s Remarks Shuling Guo, Ph.D., Executive Director, Exploratory and Doug Brooks, Ph.D., Consultant, Matapalo Pharma Rami Hannoush, Principal Scientist & Group Leader, Alex Fässler, Ph.D., COO, Bachem Holding AG, Switzerland Genetic Diseases Drug Discovery, Ionis Pharmaceuticals Consulting Services Genentech (8:05) FEATURED PRESENTATION: Rational Vaccinology: Structure-Function Relationships in the Development of Immunotherapeutic Agents Chad Mirkin, Ph.D., Professor of Chemistry, Institute for Nanotechnology, Northwestern University CMC, Quality and Regulatory Aspects RNA Therapeutics: from Bench-to-Bedside Oligonucleotide Manufacturing Technologies for Peptide Lead Discovery of Peptide API’s 8:30 (8:35) Develop Antisense Therapies for Genetic Oligo Market Expansion and Responding to the Plants as Sources for Peptide Lead Discovery Higher Molecular Weight (HMW) Peptide Impurities Diseases Capacity and Technological Challenges David Craik, Ph.D., Professor of Biomolecular Structure, – Control Strategies and Acceptance Criteria Shuling Guo, Ph.D., Executive Director, Exploratory and Joe Guiles, Ph.D., Head of Development, Institute for Molecular Bioscience, University of Ralph Schönleber, Ph.D., Vice President Research & Genetic Diseases Drug Discovery, Ionis Pharmaceuticals Agilent Technologies, Inc. Queensland, Australia Development, Bachem AG, Switzerland 9:00 From Discovery to the Clinic: Translational White Paper on Oligonucleotide Impurities Massively Parallel Synthesis and Screening of Linear Producing the Highly Potent Peptide Strategies for Oligonucleotides Nadim Akhtar, Ph.D., Principal Scientist, AstraZeneca, Peptides and Macrocycles using Peptide Microarrays Rick Dauer, Ph.D., Distinguished Engineer, Program Patrick Haslett, M.D., Executive Director of Clinical United Kingdom Lauren Goodrich, Ph.D., Scientist, Technology Innovation, Management Organization, Corden Pharma Colorado Research, Alnylam Pharmaceuticals Roche 9:30 mRNA Therapies for Acute Regenerative and Assessing the Fate and Purge of Product Related Carbon-Carbon Bond Formation on Peptides Control of Non-peptide Related Impurities in Chronic Approaches Impurities in the Manufacture of siRNAs Janos T. Kodra, Principal Scientist, Protein & Peptide APIs Originated from Materials/Consumables/ Nils Bergenhem, Ph.D., Director, Strategy and External Paul Peng, Ph.D., Principal Scientist, Process Sciences, Chemistry, Novo Nordisk A/S, Denmark Equipment Contact through Process Innovation, CVMD IMED Biotech Unit, Alnylam Pharmaceuticals Manufacturing and Storage AstraZeneca Pharmaceuticals El Djouhar Rekai, Ph.D., Head of Operation Products, PolyPeptide Group, Belgium 10:00 Networking Refreshment Break in Poster and Exhibit Hall 10:45 Development of RNAi-based Modulation of Manufacturing Process Development for PMO Engineering Potent NaV1.7 Inhibitory Peptide− Highly Pure Octreotide - Development and sFLT1 As a Novel Approach for Treatment of Bao Cai, Ph.D., Director, Process Development, Antibody Conjugates Scale-Up of a State-of-the-art SPPS Process Preeclampsia Justin Murray, Ph.D., Principal Scientist, Hybrid Modality Stefan Eissler, Ph.D., Director API Manufacturing, Bachem Anastasia Khvorova, Ph.D., Professor, Engineering, Therapeutic Discovery, AG, Switzerland RNA Therapeutics Institute, University of Massachusetts Medical School 11:15 Stereochemical Control of Antisense Antisense Oligonucleotide Purification Process: Emerging Approaches for Peptide Drug Discovery Purification of Peptides by Twin-column Oligonucleotides Enhances Target Efficacy Successes and Challenges During Scale-up Rami Hannoush, Principal Scientist & Group Leader, Countercurrent Chromatography Zhong Zhong, Ph.D., Vice President and Head of Biology, Robert Gronke, Ph.D., Senior Principal Scientist, Technical Genentech Thomas Müller-Späth, Ph.D., Senior Scientist, Institute for Wave Life Sciences Development, Biogen Chemical and Bioengineering, ETH Zurich, Switzerland 11:45 Sustained Suppression of Huntingtin mRNA and Scale Matters – The Importance of Designing Small Scaffold Proteins for Transitioning Manufacturing Development from Protein throughout the Central Nervous System Scalable Processes and Equipment Drug Discovery Clinical Supply to Registration and Pre-Commercial after Intrathecal Administration of Antisense John Batal, Director of Engineering, John Dwyer, Ph.D., Director, Protein Engineering, Ferring Process from the Small Company Perspective Oligonucleotides Nitto Avecia Research Institute Dave Garman Ph.D., Chief Technology Officer, NoNO Holly Kordasiewicz, Ph.D., Executive Director, Neuroscience Drug Discovery Department, Ionis Pharmaceuticals 12:15 Transition to Spotlight Presentation Rooms Concurrent Spotlight Presentations 12:20 nsights into the Comparison between AJIPHASE® Update on USP Standards for Sequence Fidelity of and Solid-phase Synthesis Therapeutic Peptides and Chemically Synthesized Oligonucleotides for Large Scale Oligonucleotide Manufacturing Impurity Measurements Hüseyin Aygün, Ph.D., Managing Director (CSO), Daisuke Takahashi, Ph.D., Senior Principal Researcher, Ajinomoto Co. Inc., Japan Michael Huang, Ph.D., U.S. Pharmacopeia, BioSpring GmbH, Germany Senior Science & Standards Liaison 12:50 Networking Luncheon in Poster and Exhibit Hall

For up-to-date program information and new abstracts, visit: www.TIDESevent.com 8 WEDNESDAY, MAY 9, 2018 (continued)

Oligonucleotide Oligonucleotide Delivery of Discovery, Chemistry, Peptide Discovery, Peptide Chemistry mRNA, CRISPR and Hot Preclinical and Manufacturing and Preclinical and Manufacturing and Macromolecular Topics in Oligonucleotides Clinical Controls Clinical Controls Therapeutics 1:55 Chairperson’s Remarks Chairperson’s Remarks Chairperson’s Remarks Chairperson’s Remarks Cindy Berman, Ph.D., Toxicology Consultant Ved Srivastava, Ph.D., Vice President, Chemistry, Intarcia Therapeutics Marian Gindy, Ph.D., Executive Director, Andreas Kuhn, Ph.D., Vice President RNA Pharmaceutical Sciences, Merck Research & Manufacturing, BioNTech Laboratories RNA, Germany Pharmaceuticals GmbH Delivery: Cross-Fertilizing Ideas Nonclinical Development of Oligonucleotides Peptide Preclinical and Clinical from Oligonucleotides, Peptides, mRNA Discovery and Development mRNA and CRISPR 2:00 Introduction of the Oligonucleotide Safety Working Group Engineering “Smartness” into Insulin: Glycosylated Insulins Overcoming Endosomal Entrapment mRNA Therapeutics: Ex-vivo and (OSWG) with Responsivity to Physiological Levels of Glucose in Drug Delivery with Cyclic Cell- In-vivo Modification of Antigen Jeffrey Foy, Ph.D., Director, Nonclinical Writing & Documentation, Songnian Lin, Ph.D., Director, Chemistry Modalities, Penetrating Peptides Presenting Cells Celgene Merck Research Laboratories Dehua Pei, Ph.D., Professor, Department of Kris Thielemans, M.D., Ph.D., Professor, Vrije Chemistry and Biochemistry, Universiteit Brussel and Chief Scientific Officer, (2:20) Short Updates from OSWG Subcommittees Ohio State University eTheRNA immunotherapies NV, Belgium 2:30 From Excitement to Despair to Exhilaration in 13 Months – Clinical Development of Oral for Osteoporosis Targeted Delivery of Antisense mRNA-based Cancer The Story of Arrowhead’s Move from DPCs to the Nozer Mehta, Ph.D., Principal, Peptide Technologies LLC Oligonucleotides to Pancreatic β-cells Immunotherapeutics TRiM™ Platform Shalini Andersson, Ph.D., Senior Director Robert Jabulowsky, Ph.D., Deputy Head of Thomas Schluep, Vice President, Program Management, Arrowhead Drug Metabolism & Pharmacokinetics, CVMD Project Management, BioNTech AG, Germany Pharmaceuticals Innovative Medicines, AstraZeneca, Sweden 3:00 Improved Specificity of Conjugate siRNAs through Designing Peptides for the Medici Drug Delivery System™ Design and Development of Lipid VEGF mRNA in Cardiovascular Disease Chemical Modifications Andrew A. Young, M.D., Ph.D., Chief Scientific Officer, Nanoparticles for mRNA Vaccines Anna Collén, Ph.D., Project Leader VEGF Mark K. Schlegel, Ph.D., Senior Scientist, RNAi Discovery, Intarcia Therapeutics, Inc. Marian Gindy, Ph.D., Executive Director, Project, AstraZeneca, Sweden Alnylam Pharmaceuticals Pharmaceutical Sciences, Merck Research Laboratories

3:30 Networking Refreshment Break in Poster and Exhibit Hall Delivery: Cross-Fertilizing Ideas Nonclinical Development of Oligonucleotides (continued) Peptide Preclinical and Clinical (continued) from Oligonucleotides, Peptides, mRNA CMC and Manufacturing mRNA and CRISPR (continued) 4:15 Translational Insights of Oligonucleotide ADME and Oral Delivery of Constrained Peptides to Treat Robust In Vivo Gene Editing with Essential Quality Attributes of mRNA- Toxicology: From Bench to Bedside with a GalNAc- Gastrointestinal Disorders Systemic Lipid Nanoparticle Delivery containing Lipid Nanoparticles conjugated Anti-miR Mark Smythe, Ph.D., Founder and Vice President, of CRISPR/Cas9 RNA Components Peter Lutwyche, Ph.D., Chief Technical Steven Neben, Ph.D., Senior Director, Research and Development, Protagonist Therapeutic, Australia Amy Rhoden Smith, Ph.D., Principal Scientist, Operations Officer, Arbutus Biopharma, Regulus Therapeutics Intellia Therapeutics Canada 4:45 DCR-PHXC vs. DCR-PH1: A Comparison of Nonclinical Development of Neoantigen-Based Personalized Cancer Centyrin Designer Proteins for Quality Control of mRNA for Preclinical Development Programs for siRNA Delivered Using GalNAc Vaccine NEO-PV-01 Targeted Delivery and Clinical Studies Conjugates or Lipid Nanoparticles Jesse Z. Dong, Ph.D., Vice President, Peptide Chemistry, Karyn O’Neil, Ph.D., Chief Scientific Officer, Andreas Kuhn, Ph.D., Vice President RNA Jennifer Lockridge, Ph.D., SVP, Program Development, Neon Therapeutics Arō Biotherapeutics Biochemistry & Manufacturing, BioNTech Dicerna Pharmaceuticals, Inc. RNA Pharmaceuticals GmbH, Germany

5:15 Panel Discussion Heat Shock Protein Chaperoned Long Synthetic Peptide Development of mRNA Nanomedicines mRNA Vaccines and Therapeutics: Cancer Vaccines for Delivery CMC Perspectives Mark Findeis, Ph.D., Senior Director, Research Biochemistry, Agenus, Inc. Heinrich Haas, Ph.D., Vice President, RNA Kristian Link, Ph.D., Associate Director, Formulation & Drug Delivery, BioNTech AG, Analytical Development, Moderna Germany Therapeutics 5:45 Networking Reception in Poster and Exhibit Hall Sponsored by

Register Early for Best Savings • www.TIDESevent.com • 888-670-8200 9 THURSDAY, MAY 10, 2018

Oligonucleotide Discovery, Oligonucleotide Chemistry, Peptide Discovery, Peptide Chemistry mRNA, CRISPR and Hot Preclinical and Clinical Manufacturing and Controls Preclinical and Clinical Manufacturing and Controls Topics in Oligonucleotides 7:30 Registration and Coffee

8:25 Chairperson’s Remarks Chairperson’s Remarks Chairperson’s Remarks Chairperson’s Remarks Paul Metz, Principal Consultant, Metz Claus Rentel, Ph.D., Executive Director Trishul Shah, Director, Business Development, North America, PolyPeptide Arthur A. Levin, EVP Research and Biotechnology Consulting, LLC Analytical Development/QC, Development, Avidity Biosciences Ionis Pharmaceuticals Oligonucleotide Preclinical and Clinical Development Starting Materials New Generic Peptide Regulatory Challenges CRISPR Therapeutics

8:30 HEPLISAV-B Path to Approval Transfer of Analytical Methods for DNA Registration of Generic Peptide Drug Substances, Where Are the Challenges Development of Cellular Therapies Randall Hyer, M.D., Ph.D., Vice President, and MOE Phosphoramidites from LC-Ion and How Should These Be Approached? Using CRISPR Clinical Development and Medical Affairs, Trap to LC-QTOF Mass Spectrometry Peter Larsson, Global Director Regulatory Affairs, PolyPeptide Group, Sweden Vic Myer, Ph.D., Chief Technology Officer, Head, Drug Safety and Pharmacovigilance, Editas Medicine Kyeong Eun Jung, Ph.D., Senior VP, Head of (8:50) Opportunities and Challenges of the FDA Draft Guidance ANDAs for Dynavax Technologies Corporation Oligo and R&D Division, ST Pharm. Co. Ltd., South Korea Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin 9:00 Temporary Inhibition of P53 for Presentation Title TBA Gerhard Haas, Ph.D., Vice President, Quality Assurance and Regulatory Affairs, Bachem AG, Analytics for Oligonucleotides Benjamin Kleinstiver, Ph.D., Pathology Tissue Protection: From Therapeutic Switzerland Concept to Prevention of Acute Kidney Instructor, Massachusetts General Hospital Injury in Humans following Kidney Development of a Platform Impurity (9:10) Assays for Evaluating RLD and Generic Peptide Drugs In Silico and In Vitro Transplantation and Cardiac Surgery Characterization Method for RNAi in Preparation for ANDA Elena Feinstein, M.D., Ph.D., Chief Scientific Therapeutics Annie De Groot, M.D., Founder, CEO and CSO, Epivax, Inc. Officer, Quark Pharmaceuticals, Israel Bo Pang, Ph.D., Associate Director, Analytical Development, Alnylam Pharmaceuticals 9:30 Novel Chemical Modifications for Determination by Mass Panel Discussion Heavily Modified Guides for SpyCas9- Improving Pharmacological Function Spectrometry for Oligonucleotide mediated Genome Editing of siRNAs Therapeutics Jonathan K. Watts, Ph.D., Associate Professor, Muthiah (Mano) Manoharan, Ph.D., Mark Madsen, Ph.D., Associate Director, RNA Therapeutics Institute, University of Senior Vice President of Drug Discovery, Analytical Development & Quality Control, Massachusetts Medical School Alnylam Pharmaceuticals Ionis Pharmaceuticals 10:00 Networking Refreshment Break in Poster and Exhibit Hall Oligonucleotide Preclinical and Clinical Development Analytics for Oligonucleotides Improving Peptide Synthesis and Peptide Properties Hot Topics in Oligonucleotides (continued) (continued) 10:45 Advanced GalNAc-siRNA Platform and Improving Specificity of Reverse- Bachem’s Experience with the Registration of Peptide APIs in Japan RNA Activation in NASH, Liver Failure Its Therapeutic Applications Phase Analytical Purity Methods for Valeska Kreibich, Ph.D., Specialist Regulatory Affairs, Bachem AG, Switzerland and Hepatocellular Carcinoma Torsten Hoffmann, Ph.D., Chief Scientific Oligonucleotides Nagy Habib, M.D., Head of R&D, MiNA Officer, , Germany Jonathan Neidigh, Ph.D., Analytical Therapeutics Ltd., United Kingdom Development Group Leader, Nitto Avecia 11:15 New Drug Discovery Concepts for LNA Separation of Composite Impurities of Automated Flow Peptide Synthesis: Toward Amide Bonds at Nature’s Pace Antisense Control of RNA Splicing to Therapeutics Oligonucleotides Bradley L. Pentelute, Ph.D., Professor, Chemistry, Massachusetts Institute of Technology Treat Genetic Diseases Troels Koch, Ph.D., VP & Head of Research, Claus Rentel, Ph.D., Executive Director Huw M. Nash, Ph.D., COO and CBO, RNA Therapeutics, Roche pRED, Roche Analytical Development/QC, Stoke Therapeutics Innovation Center Copenhagen, Denmark Ionis Pharmaceuticals 11:45 Inhibition of Difficult to Drug Tumor Cell Development of a Robust Analytical Considerations in the Development and Implementation of Analytical Methods Axiomer® Technology: Therapeutic and Immuno-Oncology Targets with Control Strategy for the Manufacture of for Understanding and Controlling the Chemical and Physical Stability of Oligonucleotides for Directing Next Generation Antisense Liquid Oligonucleotide Products Formulated Synthetic Peptides and Oligonucleotides Site-specific A-to-I Editing by A. Robert MacLeod, Ph.D., Vice President, Jessica Stolee, Ph.D., Senior Scientist, Biogen Paul L. Walsh, Ph.D., Principal Scientist, Merck Research Labs Endogenous ADAR Oncology and Exploratory Discovery, Antti Aalto, Ph.D., Senior Scientist, Ionis Pharmaceuticals ProQR Therapeutics NV, The Netherlands

12:15 Transition to Spotlight Presentation Rooms

For up-to-date program information and new abstracts, visit: www.TIDESevent.com 10 THURSDAY, MAY 10, 2018

Concurrent Spotlight Presentations

12:20 Oligonucleotide Downstream Optimization for Sumitomo’s Approach for Large-Scale Analytical Challenges in the Characterisation Large Scale Manufacturing Synthesis of Long RNA Oligos of Therapeutic Oligonucleotides Amanda Lewis, Senior Chemist, Oligonucleotide Division, Corden Pharma Akihiro Sakata, Senior Research Scientist, Sumitomo Chemical Co., Ltd., Japan Jordi Trafach, Characterisation Manager, Intertek Pharmaceutical Services 12:50 Networking Luncheon in Poster and Exhibit Hall

Oligonucleotide Peptide Chemistry Oligonucleotide Discovery, Preclinical Chemistry, Peptide Discovery, mRNA, CRISPR and Hot Topics in Manufacturing and and Clinical Manufacturing Preclinical and Clinical Oligonucleotides Controls and Controls

1:55 Chairperson’s Remarks Chairperson’s Remarks Chairperson’s Remarks Chairperson’s Remarks Paul Metz, Principal Consultant, Metz Biotechnology Mimoun Ayoub, Ph.D., Director and Head of North Bruce Morimoto, Ph.D., Vice President, Scientific Affairs, Stephen Spagnol, Ph.D., Senior Scientist, Sterile Consulting, LLC American and Emerging Markets, CordenPharma Celerion, Inc. Formulation Sciences, Merck Research Laboratories International, Switzerland

Oligonucleotide Preclinical and Oligonucleotide and Peptide Peptide Delivery mRNA Delivery Clinical Development Drug Product Strategies

2:00 Effects on Lp(a), Oxidized Phospholipids Microbial Aspects of Oligonucleotide Solutions Design and Development of a Novel Development of New Lipid Nanoparticles for and Monocyte Inflammation by Antisense Julie Ma, Ph.D., Associate Director, Pharmaceutical Peptide-centric Drug Delivery System mRNA-based Therapeutics Oligonucleotides Targeting Apolipoprotein(a) Development, Ionis Pharmaceuticals Sheauyu Teddy Hsu, Ph.D., Managing Director, Adepthera Kerry Benenato, Ph.D., Director, Chemistry, Nicholas Viney, Executive Director, Clinical Development, Moderna Therapeutics Ionis Pharmaceuticals

2:30 Antibody-Olignonucleotide Conjugates (AOC): Combining Peptides and Oligonucleotides in a PASylation: the Biological Alternative to Progress in the Delivery of mRNA Therapeutics Exploiting Cell Surface Receptors for Directed Nanoparticle Drug Product PEGylation Kim Askew, Ph.D., Director, Pharmacology, Translate Bio Delivery and Uptake of siRNA Marc Lemaitre, Ph.D., Principal, ML Consult and Chief Lars Friedrich, Scientist, XL-protein GmbH, Germany Arthur A. Levin, EVP Research and Development, Operating Officer, Sirnaomics, Inc. Avidity Biosciences

3:00 Some Chemical Insights of Delivery Utilizing Statistical Models for Predicting the Long-Term Design and Development of a Glucose- Optimizing mRNA Therapeutics GalNAc-siRNA Conjugates Storage of Peptide Drug Products Using Responsive Insulin Formulation Patrick Baumhof, Ph.D., Vice President Formulation & Kallanthottathil G. Rajeev, Ph.D., Senior Director, Accelerated Stability Christopher A. Rhodes, Ph.D., Chief Technology Officer, Delivery, CureVac AG, Germany Chemistry, Alnylam Pharmaceuticals Jameson Bothe, Ph.D., Associate Principal Scientist, Sensulin LLC and President & CEO, Drug Delivery Experts Analytical Sciences – MRL, Merck & Co. 3:30 Close of Conference

Register Early for Best Savings • www.TIDESevent.com • 888-670-8200 11 MEET THE PEOPLE BEHIND THE PRODUCTS & GET THE ANSWERS YOU NEED EXHIBITORS as ofJanuary 23

Diamond Sponsor: aapptec Hybio Pharma Co Advanced Analytical Interchem/AnyGen Co., Ltd. Advanced ChemTech (A Division of Interchim Event Partner: CreoSalus) Intertek Agilent Technologies. JenKem Technology AIC Kinovate Life Sciences, Inc Ajinomoto Althea, Inc LGC Gold Sponsors: AkzoNobel LI-COR Biosciences Almac Group MilliporeSigma AM Chemicals Nagase & Co. Ltd AmbioPharm Neuland Laboratories Asahi Kasei Bioprocess America Inc. Nitto Denko Avecia Silver Sponsors: Avanti Polar Lipids NOF Corporation BACHEM Pace Analytical Life Sciences, LLC BCN Peptides Phenomenex Bronze Sponsors: Berry & Associates Polymun Scientific BioAutomation PolyPeptide Laboratories BioSpring PPD BioSynthesis Exhibition Hall Grand Opening Sponsor: Purolite Life Sciences Biotage Pyramid Laboratories BioTechLogic QPS Bio-Works Sweden Quality Assistance Wednesday Night Reception Sponsor: C.A.T GmbH& Co KG Quanta BioDesign Carbosynth Senn Chemicals CEM Shen Zhen JYMed Chemical Computing Group Solvay ChemGenes ST Pharm Spotlight Presentation Sponsors: CMIC, Inc. Sunresin New Materials CordenPharma Sussex Research CPC Scientific Syngene International Ltd. GAP Peptides Thermo Fisher Scientific GE Healthcare Tosoh Bioscience LLC Glen Research TriLink Biotechnologies Registration Sponsor: Refreshment Break Sponsor: Granlen Pharmacopeia (USP) Guangzhou Ribobio Co., Ltd USV Private LTD Gyros Protein Technologies Waters Corporation Lanyard Sponsor: Herbert Brown Pharmaceutical W.R. Grace & Company Hongene Biotechnology Ltd. Zeochem AG Horizon Discovery For more information on how you can connect with key buyers at TIDES 2018, contact: Patrick Shaughnessy (Companies A-N) at [email protected] or call 857-262-5325 Aimee Croke (Companies O-Z): +1.857.504.6697 [email protected] Register Early for Best Savings • www.TIDESevent.com • 888-670-8200 12 CALL: WAYS TO EASIEST: S EMAIL: 888-670-8200 or [email protected] 3 REGISTER www.TIDESevent.com +1.941.554.3500

INDUSTRY RATES Standard Rate

3 Day Main Conference Access (Tues - Thurs) $2,699

3 Day Main Conference Access: Group 4+ Rate (Tues - Thurs) $2,499 per person

ACADEMIC/GOVERNMENT RATES* *Academic/Government rates are only extended to full-time employees 3 Day Main Conference Access (Tues - Thurs) of government, universities and university-affiliated hospitals with no 3 Day Main Conference Access: Group 4+ Rate (Tues - Thurs) industry affiliation. ADDITIONAL OPTIONS Any registered attendee may Send Your Team to TIDES add a full-day workshop pass to Industry Add on Workshop their main conference package. and Save A workshop pass provides Register your team of 4+ to receive an Acad/Govt Add on Workshop access to one (1) morning and additional $200 savings/person off the current industry rate. Secure your team’s Poster Fee for Industry (1) afternoon workshop. All workshops are held on Monday, place today by contacting Leslie Wu at Poster Fee for Academic/Government May 7, 2018 [email protected] or +1-646-895-7434.

Present a Scientific Poster at TIDES 2018 Conference Venue

Share your company’s latest research by presenting a poster at TIDES Hynes Convention Center 2018. All posters are displayed inside the exhibit hall throughout the 900 Boylston St, Boston, MA 02115 meeting.The deadline to submit a poster abstract is April 6, 2018. Book a Discounted Hotel Room at Submit a Poster Abstract at https://get.knect365.com/tides/poster/ https://lifesciences.knect365.com/tides/plan-your-visit

For details regarding our cancellation and substitution policy, visit www.TIDESevent.com

For up-to-date program information and new abstracts, visit: www.TIDESevent.com 13